Kodiak Sciences Inc., a Palo Alto, CA-based biopharmaceutical company designing and developing novel therapies for the treatment of retinal disease, closed a $34m Series B financing.
The round, which brought the total capital raised to date to above $60m, was led by a U.S.-based life sciences-focused investor.
Led by Victor Perlroth, M.D., Chief Executive Officer, Kodiak is designing and developing novel therapies for the treatment of retinal disease.
The company intends to use the funds to accelerate existing therapeutic programs and deepen its retinal pipeline including:
– KSI 201, a novel, single agent, multi-inhibitor biologic for Wet AMD; and
– KSI 401, a novel biologic that blocks activation of the complement system, potentially lessening disease activity in dry AMD patients;